(This November 8 story corrects spelling of analytics firm ESGauge, paragraph 10) By Tim McLaughlin BOSTON (Reuters) - It's nice work if you can get it. The average annual...
This biotech stock gives investors upside to cutting-edge non-opioid pain management with a trusty revenue stream from its legacy suite of treatments for cystic fibrosis.
VRTX earnings call for the period ending September 30, 2019.
Vertex Pharmaceuticals (NASDAQ:VRTX) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and...
The third-quarter earnings performance of drug/biotech companies so far has been mostly better than expected.Among the specialty pharma companies, J&J (NYSE:JNJ),...
Celgene Corporation (NASDAQ:CELG) and partner Acceleron Pharma Inc. (NASDAQ:XLRN) announced that the FDA has approved pipeline candidate Reblozyl (luspatercept-aamt) for the...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||1M||Current|
|Bullish Engulfing||1M||1||Oct 19|
|Three Inside Down||15||1||Nov 15, 2019 03:30PM|
|Engulfing Bearish||1M||2||Sep 19|
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.